doi: 10.1016/0014-2999(79)90215-2.
Circling behaviour induced by dopamine releasers and/or uptake inhibitors during degeneration of the nigrostriatal pathway
- PMID: 575095
- DOI: 10.1016/0014-2999(79)90215-2
Item in Clipboard
Circling behaviour induced by dopamine releasers and/or uptake inhibitors during degeneration of the nigrostriatal pathway
Eur J Pharmacol.
.
No abstract available
Similar articles
-
Ascorbate blocks amphetamine-induced turning behavior in rats with unilateral nigro-striatal lesions.Brain Res Bull. 1979 Jan-Feb;4(1):43-8. doi: 10.1016/0361-9230(79)90056-x. Brain Res Bull. 1979. PMID: 572739
-
The effect of dopamine uptake blocking agents on the amphetamine-induced circling behavior in mice with unilateral nigro-striatal lesions.J Pharmacol Exp Ther. 1980 Sep;214(3):651-6. J Pharmacol Exp Ther. 1980. PMID: 6772760
-
Antiparkinsonian drugs and dopaminergic neostriatal mechanisms: studies in rats with unilateral 6-hydroxydopamine (=6-OH-DA)-induced degeneration of the nigro-neostriatal DA pathway and quantitative recording of rotational behaviour.Pharmacol Ther B. 1976;2(1):41-7. doi: 10.1016/0306-039x(76)90017-9. Pharmacol Ther B. 1976. PMID: 817332 Review. No abstract available.
-
The neurological basis of motor asymmetry following unilateral nigrostriatal lesions in the rat: the effect of secondary superior colliculus lesions.Brain Res. 1978 Dec 22;159(1):211-3. doi: 10.1016/0006-8993(78)90121-x. Brain Res. 1978. PMID: 569529 No abstract available.
-
6-hydroxydopamine-induced degeneration of the nigrostriatal dopamine pathway: the turning syndrome.Pharmacol Ther B. 1976;2(1):37-40. doi: 10.1016/0306-039x(76)90016-7. Pharmacol Ther B. 1976. PMID: 772721 Review. No abstract available.
Cited by
-
Acute administration of dopaminergic drugs has differential effects on locomotion in larval zebrafish.Pharmacol Biochem Behav. 2013 Feb;103(4):792-813. doi: 10.1016/j.pbb.2012.12.010. Epub 2012 Dec 28. Pharmacol Biochem Behav. 2013. PMID: 23274813 Free PMC article.
-
Differential responses to anticipation of reward after an acute dose of the designer drugs benzylpiperazine (BZP) and trifluoromethylphenylpiperazine (TFMPP) alone and in combination using functional magnetic resonance imaging (fMRI).Psychopharmacology (Berl). 2013 Oct;229(4):673-85. doi: 10.1007/s00213-013-3128-3. Epub 2013 May 11. Psychopharmacology (Berl). 2013. PMID: 23666554 Clinical Trial.
-
Pharmacology in vivo of the phenylindan derivative, Lu 19-005, a new potent inhibitor of dopamine, noradrenaline and 5-hydroxytryptamine uptake in rat brain.Naunyn Schmiedebergs Arch Pharmacol. 1985 Apr;329(2):101-7. doi: 10.1007/BF00501197. Naunyn Schmiedebergs Arch Pharmacol. 1985. PMID: 2409454
-
Time course of striatal changes induced by 6-hydroxydopamine lesion of the nigrostriatal pathway, as studied by combined evaluation of rotational behaviour and striatal Fos expression.Exp Brain Res. 1996 Feb;108(1):69-84. doi: 10.1007/BF00242905. Exp Brain Res. 1996. PMID: 8721156
-
Designing Functionally Selective Noncatechol Dopamine D1 Receptor Agonists with Potent In Vivo Antiparkinsonian Activity.ACS Chem Neurosci. 2019 Sep 18;10(9):4160-4182. doi: 10.1021/acschemneuro.9b00410. Epub 2019 Aug 20. ACS Chem Neurosci. 2019. PMID: 31387346 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
